Back to Trades
Total Value
$5.2M
Net $3.5M sold
Filing Date
Jul 17, 2026
4 transactions
Sales
$3.5M
4 transactions
Trade Summary
On Jul 15, 2026, Mokari Atabak, Insider, sold $5.2M of CORCEPT THERAPEUTICS INC (CORT) across 4 transactions. The filing covers Common Stock and reflects net selling of $3.5M. Reported prices ranged from $19.26 to $89.43. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- CORCEPT THERAPEUTICS INC
- Ticker Symbol
- CORT
- CIK
- 0001088856
Insider Information
- Name
- Mokari Atabak
- Role
- Insider
- Location
- REDWOOD CITY, CA
Filing Details
- Filing Date
- Jul 17, 2026
- Transaction Date
- Jul 15, 2026
- Accession Number
- 0001193125-26-308058
- Form Type
- 4
- Net Trading Amount
- -$3.5M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock | 15,833 | $19.26 | Exercise | $304.9K |
| Jul 15, 2026 | Common Stock | 24,167 | $23.06 | Exercise | $557.3K |
| Jul 15, 2026 | Common Stock | 7,919 | $86.78 | Sale | $687.2K |
| Jul 15, 2026 | Common Stock | 28,460 | $87.89 | Sale | $2.5M |
| Jul 15, 2026 | Common Stock | 3,520 | $88.30 | Sale | $310.8K |
| Jul 15, 2026 | Common Stock | 101 | $89.43 | Sale | $9.0K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | CORT derivative | 15,833 | $19.26 | Exercise | $304.9K |
| Jul 15, 2026 | CORT derivative | 24,167 | $23.06 | Exercise | $557.3K |
Want live alerts when Mokari Atabak trades again?
Download Insider Trades to track CORT, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Includes 200 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 178 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 397 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
- (F2)This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on December 12, 2025 in effect at the time of this transaction.
- (F3)Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $86.20 to $87.19 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (F4)Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $87.23 to $88.21 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (F5)Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $88.24 to $89.07 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (F6)Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $89.25 to $89.43 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
- (F7)Fully exercisable.